

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>A.M. Pappas Life Science Ventures IV LP</u> <hr/> (Last) (First) (Middle) <u>P.O. BOX 110287</u> <hr/> (Street) <u>RESEARCH TRIANGLE PARK, NC 27709</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CHIMERIX INC [CMRX]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>Stockholder</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>04/16/2013</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	04/16/2013		C		892,591	A	(1)	1,047,535 ⁽³⁾	I	See Footnote ⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series F Preferred Stock	(1)	04/16/2012		C		3,168,706		(1)	(1)	Common Stock	892,591	\$0.00	0	I	See Footnote ⁽²⁾

1. Name and Address of Reporting Person* <u>A.M. Pappas Life Science Ventures IV LP</u> <hr/> (Last) (First) (Middle) <u>P.O. BOX 110287</u> <hr/> (Street) <u>RESEARCH TRIANGLE PARK, NC 27709</u> <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person*		
PV IV CEO Fund, L.P.		
(Last)	(First)	(Middle)
P.O. BOX 110287		
(Street)		
RESEARCH TRIANGLE PARK, NC		277709
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
A.M. Pappas Life Science Ventures III, L.P.		
(Last)	(First)	(Middle)
P.O. BOX 110287		
(Street)		
RESEARCH TRIANGLE PARK, NC		277709
(City)	(State)	(Zip)

1. Name and Address of Reporting Person*		
PV III CEO Fund, L.P.		
(Last)	(First)	(Middle)
P.O. BOX 110287		
(Street)		
RESEARCH TRIANGLE PARK, NC		277709
(City)	(State)	(Zip)

Explanation of Responses:

1. Upon the closing of the Issuer's initial public offering, every 3.55 shares of Series F Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
2. See attached Exhibit 99.1.
3. Includes 154,944 shares issued as payment of accrued dividends on the Series F Preferred Stock.

: [See Signatures Included in Exhibit 99.2](#) [04/16/2013](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

(2) The shares of Common Stock issuable upon conversion of the Preferred Stock are held as follows: 657,437 shares of common stock held by A.M. Pappas Life Science Ventures IV, L.P., 31,291 shares of common stock held by PV IV CEO Fund, L.P., 191,931 shares of common stock held by A.M. Pappas Life Science Ventures III, L.P. and 11,932 shares of common stock held by PV III CEO Fund, L.P. AMP&A Management IV, LLC is the general partner of each of A. M. Pappas Life Science Ventures IV, L.P. and PV IV CEO Fund, L.P. (collectively, the IV Funds), and AMP&A Management III, LLC is the general partner of each of A. M. Pappas Life Science Ventures III, L.P. and PV III CEO Fund, L.P. (collectively with the IV Funds, the Funds), and each of AMP&A Management IV, LLC and AMP&A Management III, LLC has a management agreement with A. M. Pappas & Associates, LLC whereby A. M. Pappas & Associates, LLC provides management services for the Funds. As a result, A. M. Pappas & Associates, LLC's investment committee exercises sole dispositive and voting power over the securities owned by the Funds. By virtue of these relationships, AMP&A Management IV, LLC, AMP&A Management III, LLC and A. M. Pappas & Associates, LLC may be deemed to beneficially own the securities owned directly by the Funds. Each of the foregoing entities disclaims beneficial ownership of such securities except to the extent of each of its pecuniary interest therein.

Signature of Reporting Persons:

This statement on Form 4 is filed by A.M. Pappas Life Science Ventures IV, L.P., PV IV CEO Fund, L.P., A.M. Pappas Life Science Ventures III, L.P. and PV III CEO Fund, L.P. The principal business address of each of the reporting persons is c/o A.M. Pappas & Associates, LLC, P.O. Box 110287, Research Triangle Park, NC 27709. The reporting entities disclaim beneficial ownership of the securities listed herein except to the extent of their pecuniary interest therein.

A.M. Pappas Life Science Ventures IV, L.P.

By: AMP&A Management IV, LLC

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

PV IV CEO Fund, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

A.M. Pappas Life Science Ventures III, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

PV III CEO Fund, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC
